<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03332472</url>
  </required_header>
  <id_info>
    <org_study_id>PLATEDIAN</org_study_id>
    <nct_id>NCT03332472</nct_id>
  </id_info>
  <brief_title>Telemedicine on Metabolic Control in Type 1 Diabetes Mellitus Andalusian Patients (PLATEDIAN)</brief_title>
  <acronym>PLATEDIAN</acronym>
  <official_title>Evaluation of Telemedicine on Metabolic Control in the Care of Diabetes Mellitus Type 1 Patients in Multiple Doses of Insulin Treatment in Andalusian Community</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sociedad Andaluza de Endocrinología, Diabetes y Nutrición</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sociedad Andaluza de Endocrinología, Diabetes y Nutrición</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of a 6-month telemedicine program (DiabeTIC) in patients with type 1
      diabetes mellitus (DM1) and regular metabolic control (HbA1c &lt;8%) in multi-dose insulin
      treatment (MDI) measured HbA1c vs. conventional medical care.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The substitution of face-to-face visits for telematics visits has a similar effect on
      glycemic control (measured by HbA1c) in patients with DM1 treated with multiple daily doses
      of insulin (MDI) and regular metabolic control (HbA1c &lt;8 %). It even saves costs and
      consumption of health resources, and improves the quality of life and satisfaction of
      subjects with DM1

      To evaluate the effect of a 6-month Diabetic platform on telemedicine in patients with DM1
      and regular metabolic control (HbA1c &lt;8%) on MDI treatment in the following parameters:

      A) Glycemic control: Mean glycemia, number of mild hypoglycemia / week, number of severe
      hypoglycemia / 6 months, number of hyperglycemia greater than 250mg / dl / week, number of
      episodes of ketosis / 6 months, number of episodes of ketoacidosis / 6meses , Number of
      hospital admissions due to glycemic decompensation / 6 months.

      B) Glycemic variability: Standard deviation, mean amplitude of glycemic excursions (MAGE).

      C) Fear of hypoglycemia: scale FH-15. D) Quality of life: Diabetes Quality of Life
      Questionnaire (DQoL). E) Stress: DDS questionnaire.

      F) Costs and consumption of health resources:

      -Cost-effectiveness (HbA1C)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>6 months</time_frame>
    <description>Glycosylated hemoglobin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total daily dose of insulin</measure>
    <time_frame>6 months</time_frame>
    <description>total daily doseof insulin (IU/day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total daily dose of insulin by weight</measure>
    <time_frame>6 months</time_frame>
    <description>Total daily dose by weight (IU / kg / day)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of mild hypoglycaemia</measure>
    <time_frame>6 months</time_frame>
    <description>Acude complications prior to V1: number of mild hypoglycaemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of severe hypoglycemia</measure>
    <time_frame>6 months</time_frame>
    <description>Acute complications prior to V1: number of severe hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hyperglycemia greater than 250 mg / dl / week</measure>
    <time_frame>6 months</time_frame>
    <description>Acute complications prior to V1: number of hyperglycemia greater than 250 mg / dl / week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of ketosis number of episodes of ketoacidosis</measure>
    <time_frame>6 months</time_frame>
    <description>Acute complications prior to V1: number of episodes of ketosis and number of episodes of ketoacidosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hospital admissions due to glycemic decompensations</measure>
    <time_frame>6 months</time_frame>
    <description>Acute complications prior to V1:number of hospital admissions due to glycemic decompensations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fear of hypoglycemia: FH-15 scale</measure>
    <time_frame>6 months</time_frame>
    <description>Hypoglycemia Fear test: FH-15 questionnaire (Annex)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Diabetes Quality of Life Questionnaire (DQoL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stress: DDS questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Diabetes Distress Scale (DDS) (Polonski et al, 2005)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time invested in the care of each patient</measure>
    <time_frame>6 months</time_frame>
    <description>Costs and consumption of health resources: Time invested in the care of each patient in minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of telephone calls</measure>
    <time_frame>6 months</time_frame>
    <description>Costs and consumption of health resources: Number of telephone calls</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of face-to-face visits</measure>
    <time_frame>6 months</time_frame>
    <description>Costs and consumption of health resources: Number of face-to-face visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analytics performed in the center</measure>
    <time_frame>6 months</time_frame>
    <description>Costs and consumption of health resources: Analytics performed in the center</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analytic done in domestic scope with glucometer</measure>
    <time_frame>6 months</time_frame>
    <description>Costs and consumption of health resources:Number of analytic done in domestic scope with glucometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of hypoglycaemic treatment (insulin)</measure>
    <time_frame>6 months</time_frame>
    <description>Costs and consumption of health resources: Cost in of hypoglycaemic treatment (insulin) in euros.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs and consumption of health resources</measure>
    <time_frame>6 months</time_frame>
    <description>Costs and consumption of health resources: Cost of number of admissions in emergencies and number of hospitalizations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs associated with the time spent going to the patient's hospital and family members</measure>
    <time_frame>6 months</time_frame>
    <description>Costs and consumption of health resources: costs associated with the time spent going to the patient's hospital and family members</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs associated with days lost due to complications.</measure>
    <time_frame>6 months</time_frame>
    <description>Costs and consumption of health resources: costs associated with days lost due to complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean blood glucose</measure>
    <time_frame>6 months</time_frame>
    <description>Glycemic control: Mean blood glucose (mg / dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Standard deviation</measure>
    <time_frame>6 months</time_frame>
    <description>Glycemic control: Standard deviation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">334</enrollment>
  <condition>Telemedicine</condition>
  <arm_group>
    <arm_group_label>Telemedicine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Telematics visit in front of the conventional visit face to face</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Group with conventional medical visit</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telemedicine group</intervention_name>
    <arm_group_label>Telemedicine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional group</intervention_name>
    <arm_group_label>Conventional group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with DM1 over 2 years of evolution.

          -  Age ≥18 and &lt;65 years.

          -  HbA1c prior to inclusion of the study &lt;8% (the measure being valid in the month prior
             to inclusion in the study)

          -  Intensive insulin therapy with basal-bolus MDI.

          -  Patients living in Andalusian

          -  Patients candidates for telemonitoring.

          -  Patients who have received written informed consent.

        Exclusion Criteria:

          -  Treatment with ISCI.

          -  Chronic kidney disease, liver disease, thyroid dysfunction (except hypothyroidism
             correctly treated and controlled).

          -  Pregnancy or pregnancy planning.

          -  Diabetes mellitus type 2.

          -  Severe psychological disturbances.

          -  Absence of collaboration (informed consent).

          -  Patients who are participating in other clinical studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Regional Universitario de Málaga. Unidad de Diabetes</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus: Diabetes Control and Complications Trial. Diabetes Control and Complications Trial Research Group. J Pediatr. 1994 Aug;125(2):177-88.</citation>
    <PMID>8040759</PMID>
  </reference>
  <reference>
    <citation>American Diabetes Association. Standards of medical care in diabetes--2012. Diabetes Care. 2012 Jan;35 Suppl 1:S11-63. doi: 10.2337/dc12-s011. Review.</citation>
    <PMID>22187469</PMID>
  </reference>
  <reference>
    <citation>Chase HP, Pearson JA, Wightman C, Roberts MD, Oderberg AD, Garg SK. Modem transmission of glucose values reduces the costs and need for clinic visits. Diabetes Care. 2003 May;26(5):1475-9.</citation>
    <PMID>12716807</PMID>
  </reference>
  <reference>
    <citation>Biermann E, Dietrich W, Standl E. Telecare of diabetic patients with intensified insulin therapy. A randomized clinical trial. Stud Health Technol Inform. 2000;77:327-32.</citation>
    <PMID>11187566</PMID>
  </reference>
  <reference>
    <citation>Charpentier G, Benhamou PY, Dardari D, Clergeot A, Franc S, Schaepelynck-Belicar P, Catargi B, Melki V, Chaillous L, Farret A, Bosson JL, Penfornis A; TeleDiab Study Group. The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study). Diabetes Care. 2011 Mar;34(3):533-9. doi: 10.2337/dc10-1259. Epub 2011 Jan 25.</citation>
    <PMID>21266648</PMID>
  </reference>
  <reference>
    <citation>Franc S, Daoudi A, Mounier S, Boucherie B, Dardari D, Laroye H, Neraud B, Requeda E, Canipel L, Charpentier G. Telemedicine and diabetes: achievements and prospects. Diabetes Metab. 2011 Dec;37(6):463-76. doi: 10.1016/j.diabet.2011.06.006. Epub 2011 Sep 1. Review.</citation>
    <PMID>21889388</PMID>
  </reference>
  <reference>
    <citation>Benhamou PY, Melki V, Boizel R, Perreal F, Quesada JL, Bessieres-Lacombe S, Bosson JL, Halimi S, Hanaire H. One-year efficacy and safety of Web-based follow-up using cellular phone in type 1 diabetic patients under insulin pump therapy: the PumpNet study. Diabetes Metab. 2007 Jun;33(3):220-6. Epub 2007 Mar 28.</citation>
    <PMID>17395516</PMID>
  </reference>
  <reference>
    <citation>Gómez EJ, Hernando ME, García A, Del Pozo F, Cermeño J, Corcoy R, Brugués E, De Leiva A. Telemedicine as a tool for intensive management of diabetes: the DIABTel experience. Comput Methods Programs Biomed. 2002 Aug;69(2):163-77.</citation>
    <PMID>12100795</PMID>
  </reference>
  <reference>
    <citation>Rigla M, Hernando ME, Gómez EJ, Brugués E, García-Sáez G, Torralba V, Prados A, Erdozain L, Vilaverde J, de Leiva A. A telemedicine system that includes a personal assistant improves glycemic control in pump-treated patients with type 1 diabetes. J Diabetes Sci Technol. 2007 Jul;1(4):505-10.</citation>
    <PMID>19885113</PMID>
  </reference>
  <reference>
    <citation>Bellazzi R, Larizza C, Montani S, Riva A, Stefanelli M, d'Annunzio G, Lorini R, Gomez EJ, Hernando E, Brugues E, Cermeno J, Corcoy R, de Leiva A, Cobelli C, Nucci G, Del Prato S, Maran A, Kilkki E, Tuominen J. A telemedicine support for diabetes management: the T-IDDM project. Comput Methods Programs Biomed. 2002 Aug;69(2):147-61.</citation>
    <PMID>12100794</PMID>
  </reference>
  <reference>
    <citation>Farmer AJ, Gibson OJ, Dudley C, Bryden K, Hayton PM, Tarassenko L, Neil A. A randomized controlled trial of the effect of real-time telemedicine support on glycemic control in young adults with type 1 diabetes (ISRCTN 46889446). Diabetes Care. 2005 Nov;28(11):2697-702.</citation>
    <PMID>16249542</PMID>
  </reference>
  <reference>
    <citation>Jansà M, Vidal M, Viaplana J, Levy I, Conget I, Gomis R, Esmatjes E. Telecare in a structured therapeutic education programme addressed to patients with type 1 diabetes and poor metabolic control. Diabetes Res Clin Pract. 2006 Oct;74(1):26-32. Epub 2006 Apr 18.</citation>
    <PMID>16621113</PMID>
  </reference>
  <reference>
    <citation>Montori VM, Helgemoe PK, Guyatt GH, Dean DS, Leung TW, Smith SA, Kudva YC. Telecare for patients with type 1 diabetes and inadequate glycemic control: a randomized controlled trial and meta-analysis. Diabetes Care. 2004 May;27(5):1088-94.</citation>
    <PMID>15111526</PMID>
  </reference>
  <reference>
    <citation>Rossi MC, Nicolucci A, Di Bartolo P, Bruttomesso D, Girelli A, Ampudia FJ, Kerr D, Ceriello A, Mayor Cde L, Pellegrini F, Horwitz D, Vespasiani G. Diabetes Interactive Diary: a new telemedicine system enabling flexible diet and insulin therapy while improving quality of life: an open-label, international, multicenter, randomized study. Diabetes Care. 2010 Jan;33(1):109-15. doi: 10.2337/dc09-1327. Epub 2009 Oct 6.</citation>
    <PMID>19808926</PMID>
  </reference>
  <reference>
    <citation>Anarte Ortiz MT, Caballero FF, Ruiz de Adana MS, Rondán RM, Carreira M, Domínguez-López M, Machado A, Gonzalo-Marín M, Tapia MJ, Valdés S, González-Romero S, Soriguer FC. Development of a new fear of hypoglycemia scale: FH-15. Psychol Assess. 2011 Jun;23(2):398-405. doi: 10.1037/a0021927.</citation>
    <PMID>21381839</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

